Related Experiment Video
Updated: Mar 11, 2026
Author Spotlight: Enhancing Candida albicans Detection in Catheter Infections Using Fluorescent Protein Tagging
Published on: March 22, 2024
Central venous catheter-related biofilm infections: An up-to-date focus on meticillin-resistant Staphylococcus aureus
S Esposito1, S M Purrello2, E Bonnet3
1Department of Medicine and Surgery, University of Salerno, Salerno, Italy.
Abstract:
Central venous catheters are indispensable for the long-term treatment of seriously and chronically ill patients, but their use is often associated with a variety of complications; indeed, 90% of primary bloodstream infections are related to patients having a catheter. In studies performed in France, Germany and Italy, meticillin-resistant Staphylococcus aureus (MRSA) accounted for >50% of all S. aureus isolates obtained in catheter-related bloodstream infections (CRBSIs). These infections have a serious impact on long-term disability of the patient, a substantial additional financial burden for health systems, and high costs for patients. Decreasing the rate of CRBSIs requires a multidisciplinary approach, including behavioural and educational interventions and the insertion of the correct type of catheter. Although vancomycin remains the cornerstone of empirical therapy for CRBSIs caused by MRSA, combination of different antimicrobials and new approaches are indispensable to enhance the eradication of S. aureus biofilms and to manage the patient appropriately.
Insights
Central venous catheter infections, often caused by MRSA, are a major complication for ill patients. New strategies combining antimicrobials are needed to improve treatment outcomes and reduce healthcare costs.
Area of Science:
- Infectious Diseases
- Medical Devices
- Antimicrobial Resistance
Background:
- Central venous catheters are crucial for long-term patient care but frequently lead to complications.
- Catheter-related bloodstream infections (CRBSIs) are a significant issue, with meticillin-resistant Staphylococcus aureus (MRSA) being a predominant pathogen.
- CRBSIs result in severe patient disability, increased healthcare system costs, and financial burdens for patients.
Approach:
- Implementing a multidisciplinary strategy is essential for reducing CRBSI rates.
- This approach includes educational interventions, behavioral changes, and the selection of appropriate catheter types.
- Exploring novel therapeutic strategies beyond vancomycin is necessary for effective MRSA biofilm eradication.
Key Points:
- MRSA is responsible for over 50% of Staphylococcus aureus isolates in CRBSIs across several European countries.
- Effective management of CRBSIs requires a comprehensive approach addressing both prevention and treatment.
- Vancomycin is a primary treatment for MRSA CRBSIs, but combination therapies show promise.
Conclusions:
- Reducing CRBSI incidence necessitates a combined effort involving healthcare professionals and optimized patient management.
- Further research into innovative antimicrobial combinations and biofilm eradication techniques is vital.
- Addressing MRSA in CRBSIs is critical for improving patient outcomes and reducing the economic impact on healthcare.
Related Concept Videos
01:29Biofilms
01:26Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...